Lite Strategy, Inc. (LITS)
Last updated: 2026-10-24 06:56:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Lite Strategy, Inc. (LITS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.17, with a market capitalization of $36.18M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.69 to $2.26. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$36.18M | |
$1.19 | |
$3.23 | |
$0.69 | |
$1.19 | |
138.08K | |
481.16K | |
-- | |
$2.26 | |
$0.69 | |
-- | |
-- |
Lite Strategy, Inc. (LITS) Latest Closing Stock Price
Lite Strategy, Inc. (LITS) last closed at $1.19 as of 2026-10-23 23:31:00, unchanged from the previous close of $1.19.
During the latest regular trading session, LITS traded between $0.69 and $3.23, with a volume of 138.08K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Lite Strategy, Inc. (LITS) 7-Day Stock Price Change
Over the past seven days, Lite Strategy, Inc. (LITS) moved from $1.20 to $1.17, representing a decline of 2.51% ($0.03).
The stock traded between $1.13 and $1.31 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 189.34 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
LITS 52-Week Price Position
Position in Range: 30.3%
LITS is currently trading at $1.17, placing it 30.3% of the way from its 52-week low of $0.69 to its 52-week high of $2.26. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Lite Strategy, Inc. (LITS)?
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.
Lite Strategy, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Lite Strategy, Inc. (LITS) Stock on MEXC
Eligible investors can buy real shares of Lite Strategy, Inc. (LITS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Lite Strategy, Inc. (LITS) stock price today?
2.Is LITS stock going up or down today?
3.What is LITS pre-market price?
4.What is LITS after-hours price?
5.Is LITS stock trading now?
6.Where does LITS sit relative to its 52-week high and low?
7.What sector is Lite Strategy, Inc. in?
8.What is Lite Strategy, Inc.'s market capitalization and where is it listed?
9.How is LITS valued in terms of P/E ratio and EPS?
10.Does Lite Strategy, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
LITS Stock Calculator
Estimate the value between LITS shares and USD.
LITS Shares to USD
1.00 LITS shares = 1.165 USD
Calculations are estimates based on the latest available price and are for reference only.


